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ABSTRACT 
Pre-exposure prophylaxis (PrEP) is a novel approach to human immunodeficiency 
virus (HN) infection prevention in which antiretroviral medication is used prior to potential 
HN exposure to reduce the likelihood of infection. PrEP may be a useful adjunct to current 
prevention approaches in the absence of an effective HN vaccine or microbicide. Current 
and planned clinical trials seek to answer critical questions about the safety and efficacy of 
PrEP in at-risk populations. While these clinical trials are likely to answer many questions 
about the role of PrEP in HIV prevention, additional clinical, social, and ethical questions will 
be raised. In anticipation of the results of these trials, the public health community should act 
proactively to answer many of the questions surrounding the use of PrEP in populations 
outside the context of clinical trials. By beginning to answer the myriad of questions likely to 
arise with this prevention strategy now, the public health system can better prepare 
themselves and the communities they serve for the implementation of PrEP or other HN 
prevention strategies in the future. 
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INTRODUCTION 
Pre-exposure prophylaxis (PrEP) is a novel approach to human immunodeficiency 
virus (HN) infection prevention in which antiretroviral medication is used prior to potential 
HN exposure to reduce the likelihood of infection. In the absence of an effective vaccine or 
microbicide, PrEP has gained popularity as a possible adjunct to current prevention strategies. 
Clinical trials investigating the safety, efficacy and viability of pre-exposure prophylaxis 
strategies among high-risk populations are now underway in the United States and 
internationally. 
It is not yet known if PrEP will be a safe or effective approach to HN prevention. 
The planned and on-going clinical research studies seek to answer questions of safety and 
effectiveness. If clinical trials do demonstrate safety and efficacy, public health officials will 
be faced with significant clinical, ethical and logistical challenges related to the 
implementation of PrEP in their communities. Additional studies will be necessary to help 
determine how PrEP will be used in clinical and public health practice. Guidelines for use in 
at-risk populations will need to be developed quickly. Persons at-risk will need to be rapidly 
identified and appropriate education and outreach initiated. 
PrEP should be distinguished from post exposure prophylaxis (PEP), a prevention 
strategy in which antiretroviral medication is administered closely following a potential HN 
exposure. PEP has been extensively studied in prevention ofHN infection following 
occupational exposures and has recently been expanded for use following high-risk sexual 
exposures. 
This paper will examine the evidence supporting the use of pre-exposure prophylaxis 
for HN, starting with a review of other biomedical prevention strategies, with an emphasis on 
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HIV PEP and strategies for preventing the transmission ofHIV infection from mother to 
child. Additional scientific evidence supporting the use of PrEP will be summarized and the 
major clinical trials of PrEP currently planned or emolling will be reviewed. Finally, current 
and anticipated challenges to the national, regional and local public health systems will be 
reviewed and recommendations for action provided. 
THE HIV EPIDEMIC 
In June 1981, the U.S. Center for Disease Control and Prevention (CDCYissued its 
first warning about a rare form of pneumonia occurring among a small group of young gay 
men in California. The unusual pneumonia was later included in a case definition of a new 
syndrome, Acquired Immune Deficiency Syndrome (AIDS), a term established in 1982. In 
1983, the U.S. Public Health Service issued recommendations for preventing the transmission 
of AIDS through sexual conduct and blood transfusion. That same year, female sexual 
partners of men with AIDS were added as the fifth at-risk group, joining a list of risk factors 
that already included male homosexuality, intravenous drug abuse, Haitian origin and 
hemophilia A. In 1984, the agent responsible for AIDS, HIV, was discovered. Also in 1984, 
the CDC recommended abstinence from intravenous drug use and reduction of needle sharing 
as the primary strategy to reduce the transmission of the HIV virus among intravenous drug 
users (IDU).1 Since that time, over 60 million people have been infected with HIV 
worldwide, including the approximately 40 million persons estimated to be living with 
HIV I AIDS today. 
Prevention methods that protect against exposure to HIV, such as those recommended 
by the CDC early in the epidemic: sexual abstinence, monogamy with an uninfected partner, 
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consistent and correct condom use, avoidance of intravenous drug use and consistent use of 
sterile equipment by those unable to cease intravenous drug use, remain the most effective 
prevention measures. The most widely used prevention methods, including abstinence, 
partner reduction and condom use, have shown efficacy in preventing the transmission ofHIV 
and, in certain settings, these behavioral interventions have been shown to slow the rate of 
HIV transmission. Unfortunately, behavioral interventions are inconsistently utilized, fail to 
be universally effective, and therefore have been inadequate to control the HIV pandemic. 
Global Outlook 
HIV I AIDS cases have been reported in all regions of the world, though the majority of 
persons of living with HIVIAIDS (95 percent) and the majority of new HIV infections and 
HIVI AIDS related deaths occur in low- and middle-income countries. The nations of sub-
Saharan Africa carry the highest burden of disease with a prevalence rate estimated to be over 
20 percent in six sub-Saharan African nations. 2 
UNAIDS/WHO estimates that over 14,000 persons were infected with HIV each day 
in 2003.2 Of the new infections, 12,000 occurred in persons aged 15 to 49 years of age, 50 
percent of who were 15 to 24 years old. Nearly 2,000 of the new infections occurred in 
children under 15 years of age. 3 
Women comprise an increasing portion of adults living with HIV I AIDS, comprising 
nearly half of all AIDS cases at the end of2004. While this trend is occurring in most regions 
of the world, it is particularly notable in sub-Saharan Africa where women represent 
approximately 57 percent of adults living with HIVI AIDS? Gender inequality in social and 
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economic status and in access to prevention and care services increases the vulnerability of 
women to HIV.4 
Global Summary of the HIV/AIDS Epidemic 
December 2004 
Total Persons Living with HIV/AIDS in 2004 
Total 39.4 million (35.9-44.3 million) 
Adults 37.2 million (33.8-41. 7 million) 
Women 17.6 million (16.3-19.5 million) 
Children under 15 years 2.2 million (2.0-2.6 million) 
Total Persons Infected with HIV in 2004 
Total 4.9 million (4.3-6.4 million) 
Adults 4.3 million (3.7-5.7 million) 
Children under 15 years 640,000 (570,000-750,000) 
Death from HIV/AIDS in 2004 
Total 3.1 million (2.8-3.5 million) 
Adults 2.6 million (2.3-2.9 million) 
Children under 15 years 510,000 (460,000-600,000) 
• 0 Source: UNAIDSIWHO Global Summary of the HIVIAIDS Ep1dem1c 
United States 
The CDC estimates that there are 850,000 to 950,000 persons in the United States 
living with HIV, including 180,000 to 280,000 persons who do not know they are infected. 
From 2000 to 2003, in the 32 states that used confidential, name-based reporting ofHIV and 
AIDS cases for at least the past 4 years, the overall annual rate of diagnosis of HIV I AIDS 
remained stable. However, racial and gender disparities in HIVIAIDS continue to worsen. 
For example, rates among non-Hispanic black females were 19 times higher than rates among 
non-Hispanic white females during the reporting period. The racial disparities seen in 
HIV I AIDS incidence underscore the need for continued emphasis on programs targeting 
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females in racial and etlmic minority populations to reduce the number of cases of 
HIV/AIDS.5 
North Carolina 
Over 2,100 new cases ofHIV disease (HIV and AIDS cases) were reported in North 
Carolina in 2003. The overall infection rate for HIV was 25.2 per 100,000 persons. Rates of 
HIV I AIDS have remained stable over the past five years, though increases are noted among 
African Americans and Hispanics. Sexually transmitted infections, including HIV infection, 
remain disproportionately represented among racial and etlmic minorities. The rate ofHIV 
for Hispanics (25.4 per 100,000) is over two and a halftimes greater than that for whites and 
the rate for non-Hispanic blacks (76.6 per I 00,000) is eight times greater than that for whites. 
Also of note, the infectiqn rate for black females (51.9 per 100,000) was over 14 times higher 
than that for white, non-Hispanic females (3.6 per 100,000).6 
PREVENTING HIV INFECTION 
The trends in infection rates reviewed above highlight the importance of identifying 
new methods ofHIV prevention. With the burden ofHIV infection in certain regions of the 
world, especially sub-Saharan Africa, reaching staggering proportions, the need for effective 
preventive approaches to halt or reduce the rate of new infections is well recognized. Efforts 
remain focused on new biomedical interventions, such as vaccines and microbicides to 
prevent new HIV infection. 
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HIVVaccine 
There are many scientific challenges to the development of an effective HIV vaccine 
and, unfortunately, the vaccine candidates currently under investigation appear unable to 
produce protective immunity. The first phase III HN/AIDS vaccine trials have shown a 
complete lack of efficacy. Given the difficult, and currently unresolved, scientific challenges 
to eliciting antibodies by vaccination that are capable of neutralizing HN, these negative 
results were expected by many investigators in the field. 7 Since current vaccine candidates 
are unlikely to be adequately effective, behavioral interventions remain critical to HN 
prevention. 
Microbicides 
The development of safe and effective vaginal microbicides, chemical compounds that 
can be applied topically to inactivate HIV, is another focus of current prevention research. 
Microbicides may be especially important to women, especially in the developing world, 
when male sex partners are unwilling to use condoms consistently or at all. Current efforts 
are aimed at developing intravaginal and intrarectal topical formulations that either directly 
inactivates HN, stop HN from attaching or entering, or prevent HN replication and 
dissemination. Ideally, an anti-HN microbicide would act against HN in multiple ways, 
combining these approaches. Additionally, a microbicide should ideally act as a 
contraceptive, preventing unintended pregnancies. To be useful, the microbicide agents will 
need to be safe and effective following vaginal or rectal administration and cause minimal or 
no genital symptoms despite repeat use8 
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A safe and effective anti-HIV microbicide is not yet available; however there are 23 
microbicide products in various stages of clinical development. Multicenter phase IIII safety 
and phase II/III efficacy studies are currently planned or underway in diverse geographic 
locations. For the majority of these products, no information is available regarding mucosal 
safety or efficacy following extended vaginal or rectal exposure.9 The ultimate role of 
microbicides in HIV prevention efforts remains to be determined and the time course for 
broad clinical trials of a microbicide suggests that it will be several years before a microbicide 
is available for widespread clinical use. 
BIOMEDICAL PROPHYLAXIS: LESSONS FROM CURRENT STRATEGIES 
With an effective HIV vaccine or microbicide still years away, HIV prevention experts 
have begun to explore alternative biomedical approaches to the prevention of new infection. 
One approach that has gained significant support in the past 3 years is pre-exposure 
prophylaxis (PrEP). Animal studies suggest the possible effectiveness of a single agent 
antiretroviral for the prevention of new infection and clinical researchers are now exploring 
the use of antiretrovirals as a preventative treatment in HIV negative humans. 
The concept of providing a preventive medication prior to exposure to an infectious 
disease is not a new one. For example, travelers to areas endemic for malaria often receive 
antimalarial medication to prevent infection in the case of exposure to the malaria parasite. 
Historically the use of antiretroviral medications to prevent HIV infection has occurred in two 
settings: following occupational exposure to HIV and in the prevention of mother to child 
transmission. These two prophylaxis strategies provide supportive evidence for PrEP and 
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have also raised many important questions that should be considered as PrEP strategies are 
developed and studied. 
HIV Post Exposure Prophylaxis 
Medical treatment following exposure is less effective than preventing HN infection 
by avoiding exposure. 10 However, post exposure prophylaxis (PEP) is an accepted HN 
prevention strategy in a select group of at-risk individuals. PEP has been primarily studied 
and utilized in occupational exposure settings. PEP was widely accepted after the publication 
of a retrospective, case-control study of health care workers having occupational, 
percutaneous exposure to HN-infected blood. After controlling for other risk factors for HN 
transmission, post exposure use of zidovudine (AZT) reduced the odd of acquiring HN 
infection by more than 80 percent II 
Subsequent studies have examined the use of PEP for non-occupational exposure (for 
example, sexual or drug use) to HIV. Recent studies have suggested that it is indeed safe, 
feasible and cost-effective to deliver PEP to reduce the risk ofHN infection in non-
occupational exposures. I2.I 3 
While limited, the available data suggest that the availability of PEP does not increase 
risk behavior among users. Several trials have suggested that in the setting of intensive 
counseling on risk reduction, the availability of PEP did not result in a higher rate of high-risk 
sexual activity.I4-I 6 Martin and colleagues examined the relationship between PEP and risk 
behavior in a group of approximately 400 adults who received PEP following high-risk sexual 
or drug related exposures. The study found that in the 12 months following the exposure and 
PEP, after 12 months 73 percent of participants reported a decrease in the frequency of risk 
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behaviors and 83 percent did not request additional PEP.15 Another study found that PEP was 
sought and utilized most commonly by individuals who usually practice safe sexual or 
injection drug practices but experience a lapse. However, the same study also found that it 
was difficult to deliver PEP in a timely manner following exposure to HN, perhaps 
diminishing its efficacy.12 
A high-risk cohort of200 HN negative homosexual males in Brazil received 
preventive counseling, PEP instruction and 4-day starter packs of two HN antiretroviral 
medications to be administered immediately after exposure to blood or semen. Participants 
reporting any high-risk sexual exposure at baseline and 18 months were 57 and 54 percent 
respectively. During the study period PEP was initiated 92 times by 65 participants. Men 
who began taking PEP after a self-identified high-risk exposure were evaluated within 96 
hours; 92 percent met the event eligibility criteria (clinician-defined high-risk exposure). 
Seroincidence was 0.7 per 100 person-years (one seroconversion) among men who took PEP 
and 4.1 per 100 person-years among men who did not take nPEP (11 seroconversions). After 
analysis of the trial results, study authors concluded that reported high-risk behaviors declined 
in the cohort with access to PEP. A lower HIV seroincidence was noted among PEP users, 
though the limited statistical design and power ofthe analysis did not allow direct 
measurement of PEP efficacy. 16 Additional studies, including cohort studies of rape 
survivors, have suggested a benefit to PEP when initiated within 72-96 hours of possible 
exposure. 12 
The CDC has issued guidelines for occupational PEP. 17 Additional recommendations 
for the use of PEP in non-occupational exposures are also available from the CDC, however 
previously the CDC did not advocate the use of PEP in non-occupational settings.18 
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Guidelines released in F ebl:uary 2005 now include recommendations for the use of a 28 day 
course of combination antiretroviral therapy for persons who have had non-occupational 
exposure to blood, genital secretions or other potentially infected body fluids of a person 
known to be HIV infected, or when the exposure represents a substantial risk for HIV 
transmission, and when the person seeks care within 72 hours of exposure.12 
State guidelines for non-occupational PEP have been developed and issued in New 
York, Rhode Island and Califomia.19"20 .2l Massachusetts has issued a clinical advisory 
recommending that clinics create protocols to address PEP issues.22 Recommendations for 
the use of PEP following sexual assault have been adopted in many states as well. 
Internationally, many nations, including South Africa, France, Italy, Spain and Australia, have 
policies recommending the use of PEP for non-occupational exposures.Z3 
Overall, PEP for non-occupational exposure was well tolerated. According to the 
U.S. Non-occupational PEP Surveillance Registry, for 107 high risk exposures for which PEP 
was taken, the regimen initially prescribed was stopped or modified in 22 percent of cases; 
modifications or stops were reported because of side effects in half of these instances.24 
Prevention of Mother to Child Transmission 
The use of antiretrovirals to prevent the transmission ofHIV from an infected mother 
to her infant has been one of the most successful HIV prevention strategies to date. 
Administration of antiretroviral medication to an HIV-infected mother during labor, or earlier 
in pregnancy, and to the infant postpartum dramatically reduces the rate of peri-natal HIV 
infection. In 1994, a prospective, randomized controlled trial demonstrated AZT 
administered to HIV -infected women during pregnancy and labor and to infants for 6 weeks 
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following delivery reduced peri-natal transmission by 67 percent, from 25.5 percent to 8.3 
percent. 25 Similar approaches, using the antiretroviral agent nevirapine or combination 
antiretroviral therapy combined with elective caesarean section and avoidance of 
breastfeeding, have reduced transmission rates to 1-2 percent.26 The mechanisms for these 
reductions are multi-factorial and are likely to involve both pre- and post exposure effects. 
Pre-exposure, antiretroviral treatment prevents cross-placental and intrapartum HIV 
transmission by reducing the viral load of the mother. Antiretroviral medications that cross 
the placental barrier also offer drug exposure to the fetus. Administration of antiretroviral 
therapy to the infant following delivery comprises the post exposure prophylactic component. 
Information on the safety of the various antiretroviral therapy regimens suggests that 
short-course regimens are generally well tolerated with mild and rare side effects for the 
woman and her infant. Concern is greater for women taking antiretroviral therapy for 
extended periods oftirne, especially those women who would not otherwise require 
antiretroviral treatment. Recent studies have focused on the risk of drug resistance with short-
course regimens. Drug resistance has been reported for pregnant women and, less commonly, 
in children. Resistance is known to occur quickly in women and infants exposed to single-
dose nevirapine. 27 The clinical consequences of viral resistance following mother to child 
transmission prophylaxis are unclear. 28 Concerns about resistance must be balanced along 
with other risks and benefits of MTCT prophylaxis, including the widespread availability, 
simplicity and practicality of the single-dose NVP regimen. The risk of antiretroviral 
resistance also must be considered with the use of a single antiretroviral agent for PrEP in a 
population at high-risk for HIV infection. 
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Additional Examples of Pre-Exposure Prophylaxis 
Prophylactic strategies are utilized in non-HN settings as well. One of the most 
widely accepted prophylactic strategies is the use of anti-malarial medications to prevent or 
attenuate malaria infection in visitors to malaria endemic areas. Additionally, pre-exposure 
prophylaxis of sexually transmitted infections has demonstrated usefulness in certain 
populations and during outbreaks. 
Malaria Chemoprophylaxis 
Malaria is an infectious agent for which chemoprophylaxis is a standard preventive 
measure. The decision to use anti-malarial prophylaxis requires a careful risk-benefit analysis 
weighing the risk of acquiring potentially serious malarial infection against the risk of harm 
from the prophylactic agent. Malaria prevention for travelers to endemic areas combines 
behavior modifications such as the use of insect repellants and protective clothing and nets 
with prophylactic medications. Although anti-malarial medications do not prevent infection 
with the malaria parasite, they help prevent the development of clinical illness. A wide 
variety of anti-malarial agents are available, but most are associated with significant side 
effects. In addition, anti-malarial drugs, particularly newer agents, are costly. Despite 
imperfect protection, toxicity, and high cost, chemoprophylaxis combined with behavioral 
interventions to reduce mosquito exposure is considered the standard of care for persons 
traveling to malaria-endemic areas and has made visits to these areas safer29 
12 
Mass Treatment of Sexually Transmitted Infections 
The epidemiologic approach to the treatment of sexually transmitted infections (STI) 
involves the administration of antibiotic therapy to a population based on increased risk rather 
than for symptoms or proven infection. In high-prevalence populations where rates of 
exposure to STI are high, mass treatment likely works both by preventing and treating 
infections. Although mass treatment is not standard practice in the United States, the 
approach has been studied in international setting for the prevention and control of STI 
including Chlamydia, gonorrhea and syphilis. Additionally several trials have demonstrated 
that STI treatment can reduce the transmission ofHIV.30 •31 "32 •33 The degree to which this 
approach may be effective depends on a variety of factors including pathogen and host 
factors. Problems with mass treatment include the cost of providing treatment, difficulties 
with adherence, challenges eliciting community support, and the risk of emerging drug 
resistance. 34 Similar issues arise with the use of antiretrovirals for HIV PrEP. 
PRE-EXPOSURE PROPHYLAXIS: SUPPORTING EVIDENCE 
As discussed above, antiretrovirals appear to prevent or reduce HIV transmission in 
post-exposure prophylaxis and in mother-to-child transmission settings. Additional evidence 
supporting the use of PrEP for HIV prevention comes from animal studies and several small 
clinical trials. 
Animal Studies and Early Trials 
13 
The first studies using animal models of pre-exposure prophylaxis were conducted 
using the antiretroviral agent nevirapine. A variety of animal models demonstrated the 
effectiveness of nevirapine in preventing or delaying HN infection. 35 
One of the first reports on the feasibility of PrEP for the prevention of new HN 
infection in humans was first presented in 2002 at the XVth International AIDS Conference in 
Barcelona. This phase I/II trial, known as HNHOP 101, provided a 200mg tablet of 
nevirapine once weekly, twice weekly, or every other day to a cohort of men and women in 
the Baltimore area at high risk for HIV infection. The group included sex partners ofHN-
positive persons, gay men and injecting drug users. In this trial, none of the participants 
reported significant side effects from the medication, though increases in liver function tests 
were seen more frequently in participants receiving the higher doses of nevirapine. 36 The 
authors reported that risk -taking did not increase during the study and none of the participants 
became HIV positive during the course of the trial. However, the trial was designed to assess 
the safety of the use of antiretroviral medications as PrEP, not to assess the effectiveness of 
PrEP nor its impact on risk behavior. However, the study was successful as "proof of 
concept". 
While nevirapine appeared promising as a PrEP agent, concerns about liver toxicity, 
particularly in women with intact immune systems, were raised in other trials. Notably, a 
study published in the Journal of Acquired Immune Deficiency Syndromes in August 2004 
found that HN-negative people appear to have a higher risk of side-effects when exposed to 
nevirapine, according to a review of case reports and toxicity reports from people exposed to 
the drug as a component of PEP after potential exposure to HN. The authors suggest that 
autoimmunity may be at the root of these toxicities, since when severe adverse reactions have 
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occurred in HIV -positive people (at a rate ofless than 1 percent), they have tended to be when 
CD4 counts were high. They conclude, "Although precise estimates of the risk for severe 
hepatotoxicity are not available, the risk appears to be higher than in HIV infected persons .... 
Therefore, non-HIV infected individuals should not receive PEP or other prophylaxis 
regimens that include multiple doses of nevirapine."37 These findings have raised concerns 
about the safety of using nevirapine in pre-exposure settings. Subsequently, planned clinical 
trials using nevirapine in HIV negative persons have been discontinued. 
Table 1. Ideal Chemoprophylactic Agent 
for Pre-Exposure Pro h laxis38 
Blocks infection 
Long half-life 
High penetration into target tissues 
Low toxicity 
High tolerability 
High barrier to resistance 
Inexpensive to produce 
Stable in heat and humidity 
No food requirement for dosing 
Adapted from Grant R. Pre-exposure prophylaxis. Twelfth Conference on Retrovirnses and 
Opportunistic Infections, Boston, abstract 137, 2005. 
Tenofovir 
Given significant concerns about the safety of nevirapine in HIV negative persons, 
attention turned to other antiretroviral agents with an excellent safety profile and other 
features conducive to PrEP. The antiretroviral medication tenofovir has been selected for 
planned trials of PrEP because of its safety and efficacy. Animal studies with tenofovir have 
shown that tenofovir, administered before and immediately after a single retroviral exposure, 
can prevent the transmission of a virus similar to HIV in monkeys and delay and attenuate 
infection in animals receiving serial exposure. 39•40 
Tenofovir meets many of the requirements for the ideal chemoprophylactic agent (table 
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1). Approved by the Food and Drug Administration in 2001, experience with tenofovir in the 
treatment of HIV infection is extensive. Adverse effects with tenofovir are rarely reported 
with the most common side effects including nausea, decreased appetite and flatulence. 
Tenofovir can be dosed as one pill taken once daily and reports document excellent 
adherence.41 The CDC cites these features when explaining the rationale behind the use of 
tenofovir in multiple international clinical trials, 
Tenofovir has been selected for investigation as chemoprophylaxis against HIV in high-
risk individuals because of its unique pharmacologic profile. In addition to the 
convenience ofbeing a once-daily single tablet with a safety profile comparable to 
placebo among HIV-infected persons, it has striking anti-HIV potency and a low 
potential for selection of resistant viruses. Each of these properties is necessary given 
the realities of the intended target populations.42 
OVERVIEW OF PLANNED PRE-EXPOSURE PROPHYLAXIS RESEARCH STUDIES 
As of April2005, there are several major human trials ofHIV PrEP underway or in 
the planning stages. These trials focus on the safety and/or efficacy of PrEP in high-risk 
women (Cameroon, Ghana, Nigeria), high-risk men (Malawi), sexually active young adults 
(Botswana), injection drug users (Thailand) and MSM (United States). These planned or 
ongoing trials are summarized in Table 2. A planned National Institutes of Health trial of 
PrEP in commercial sex workers in Cambodia has been placed on hold after sex workers, 
activists and the Cambodian Department of Health raised concerns about the ethics of the trial 
design. Additionally, activists have opposed trials in Cameroon and Thailand citing concerns 
about the safety of the trial design and ethical treatment of trial volunteers. These 
controversies will be discussed further below. 
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Family Health International/Gates Foundation 
Family Health International (PHI) received a grant from the Bill and Melinda Gates 
Foundation to conduct phase II studies of PrEP in high-risk, HIV -negative adults in Ghana, 
Nigeria, Cameroon and Malawi. The trials are double-blinded, randomized and placebo-
controlled. The trials are anticipated to last approximately 2 years, beginning with a 6 month 
screening phase followed by a 6 month recruitment phase and 12 months of study drug use for 
participants. The primary endpoints of the study are safety and efficacy. The safety of 
tenofovir for PrEP will be determined by adverse event reports and laboratory measurements. 
For the PHI trials, efficacy oftenofovir for the prevention ofHN acquisition will be 
determined by the rate of HN seroconversion. Trial volunteers will receive counseling that 
they are participating in a research study and that they may be receiving placebo. Participants 
will receive counseling in HN prevention including education on safer sexual practices and 
be provided with condoms. Overlapping behavioral research is also being conducted to 
determine the acceptability of the intervention among participants, their partners, and the 
community. Additionally the barriers and facilitators to the PrEP strategy will be studied to 
assist in the translation of trial results to HN prevention program planning. Study completion 
is scheduled for mid-2006 after which trial results will begin to become available. 
CDC Sponsored Trials 
The U.S. Centers for Disease Control (CDC) is sponsoring three separate trials to 
answer important questions about the safety and efficacy of daily oral tenofovir for the 
prevention of new HIV infection in populations at high risk for infection worldwide. The 
three trials seek to enroll a total of 3,200 participants from three countries: Botswana, 
Thailand and the United States. The Botswana and Thailand trials are designed to determine 
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if once daily tenofovir is safe and effective in reducing HN transmission among heterosexual 
and intravenous drug users, respectively. The U.S. trial is designed to assess the tolerability 
oftenofovir in men who have sex with men (MSM) but is not adequately powered to assess 
efficacy in this population. Subsequent trials with larger numbers of participants would be 
required to demonstrate effectiveness in the MSM population.43 
The CDC studies are also designed to address issues pertinent to the design of future 
PrEP trials and to the implementation of similar PrEP strategies. These issues include the 
impact of PrEP on risk behavior, medication adherence and acceptability, and drug resistance. 
Volunteer Protections 
To ensure the scientific validity and the maintenance of ethical standards, each trial 
has undergone review and has been approved by institutional review boards (IRBs) at the 
sponsoring institution and by each host country and study site. Independent data and safety 
monitoring boards (DSMB) have been established to review data on enrollment, safety and 
efficacy at standard intervals. The DSMB will review trial findings on an ongoing basis to 
determine that it is safe to continue the trial. During the phase III portion of the trials, the 
DSMB will determine at which point the study results are conclusive. 
18 
Table 1. Major PrEP Trials, March 2005. Adapted from Szekeres G et al. 2004 44 
Sponsor Trial Aims Study Population Target Study Enrollment Notes 
Location Enroll me Duration Schedule 
nt 
FHI/Gates • Evaluate the safety and Ghana 400 Enrollment on hold in Foundation efficacy of TDF for PrEP Began Cameroon while 
• Determine acceptability of Nigeria high-risk 400 summer government PrEP among participants, their women 2004 investigates partners and the community 2 years allegations of 
• Identify barrier and facilitators Cameroon 400 unethical and unsafe 
to translating study results into Malawi heterosexual 400 To begin practices from 
effective HIV prevention men summer activists. 
planning 2005 
CDC • Evaluate biological and Thailand IDUs 1,600 30 months Began fall Enrollment halted 
behavioral safety ofTDF for 2004 after protesters 
PrEP raised concerns 
regarding just 
treatment of 
volunteers. 
• Evaluate efficacy of TDF for Botswana sexually 1,200 32 months To begin 
PrEP active adults spring 2005 
• Assess adherence to study United high-risk 400 2 years Began fall 
drug States MSM 2004 
• Evaluated TDF resistance in 
participants who seroconvert 
• Bone density, bone metabolism 
will be evaluated in a subset of 
participants 
NIAID • Evaluate safety and efficacy of 
TDFfor PrEP Study halted after 
• Evaluate safety ofTDF in protestors raised participants with hepatitis B Cambodia female CSW 960 1 year On hold concerns regarding 
• Assess adherence to study the ethics and safety drug oftrial design. 
• Evaluate changes in risk 
behavior 
PrEP Pre-exposure prophylaxis; TDF tenofovir DF; IDUs intravenous drug users; MSM men who have sex with men; CSW commercial sex workers 
CLINICAL TRIALS CONTROVERSY 
In certain participating countries, the PrEP trials have met significant resistance from 
HN I AIDS advocacy groups. These protests illustrate many of the challenges facing researchers 
and pharmaceutical companies when conducting clinical trials in developing nations. In recent 
years, the increasingly global nature of health research has highlighted questions regarding the 
ethics of trial design, conduct and follow-up. While research studies conducted by scientists 
from more prosperous nations in poorer countries more heavily burdened by disease may reflect 
efforts to help address a public health problem, these studies may reflect an assessment that a 
foreign location is more convenient, inexpensive, and efficient. This may impose ethically 
inappropriate burdens on the host country and on trial participants. This potential for 
exploitation has lead to an effort to ensure that protections are in place for participants in 
international clinical trials. 
Sponsoring or conducting research in developing countries often poses special challenges 
arising from cultural differences, such as distinct histories, political, judicial and economic 
systems. In countries with a significant burden of poverty, primary health care services are often 
inadequate and a majority of the population cannot access basic health care services. As a result 
of these adverse conditions, persons in these countries are often vulnerable in situations in which 
the improved health care is offered, including clinical trials. Further, participants in developing 
nations may not fully understand the nature of informed consent and may lack adequate funds to 
obtain health care following trial participation. Groups such as commercial sex workers and 
intravenous drug users are seen as especially vulnerable because they lack political or economic 
bargaining power to negotiate the terms of a trial as well as the resources to acquire the 
necessary treatment or insurance if they contract the virus during the test. 45 
The National Bioethics Advisory Committee (NBAC) issued a report in 2001 titled 
"Ethical and Policy Issues in International Research: Clinical Trials in Developing Countries."46 
The NBAC report outlines the essential requirements for the ethical conduct of clinical trials. 
These requirements include both procedural and substantive items and builds on the three basic 
ethical principles outlined for research involving human participants in the 1979 Belmont 
Report: respect for persons, beneficence and justice. 47 The expanded recommendations include 
several principles that are crucial to the design and success of international trials ofPrEP. The 
conflicts over PrEP trials in Cambodia, Cameroon, and Thailand highlight the importance of 
community involvement, assessment and outreach in trial design and early implementation. 
l 
Cambodia t 
The National Institutes of Health awarded a grant to the University of California-San 
Francisco to conduct a trial of tenofovir' s effectiveness in preventing the transmission of HN in 
960 Cambodian women, the majority of who were commercial sex workers. Cambodian Prime 
Minister Hun Sen ordered the trial to stop in August 2004, citing possible harmful effects of the 
study drug on trial participants and inadequate provisions for follow up care for trial participants. 
In July, representatives of the Women's Network for Unity, an organization of Cambodian 
commercial sex workers, interrupted a session at the XV International HIV Conference in 
Bangkok to protest the trial. The group raised concerns about the study design and said they 
would not participate in the trial unless they were provided with 30 years of health insurance to 
cover possible adverse consequences of trial participation. 
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Cameroon 
On February 3, 2005, the Ministry of Health of Cameroon announced that it was 
suspending the FHI sponsored clinical trial oftenofovir for HN PrEP, citing "failings 
in .. .implementation." The trial, which involves HN-negative commercial sex workers in the 
city of Douala, came under fire from activist groups, most notably ACT UP/Paris, who alleged 
that the trial violated ethical norms and called for it to be halted. ACT UP/Paris claims that the 
study recruited vulnerable participants without providing adequate HN/AIDS prevention 
information or treatment. Cameroon's Health Minister, Urbain Awono, stated, "The decision to 
suspend the trial comes after an audit commission of doctors recently delivered a report on how 
the trial was being conducted." A spokesperson for FHI denied the accusations. FHI is 
addressing the health minister's concerns and making progress towards implementing 
recommendations from the ministry of health including changes in administrative procedures and 
bolstering partnerships with local HN prevention organizations to provide better counseling and 
support services to trial participants. On February 14, 2004, the health ministry did agree to 
allow the follow-up of participants currently enrolled in the trial.48 
22 
"Tenofovir makes me vomit." ACT UP activists staged demonstrations against the 
PrEP trials at the 15th International AIDS Conference. From Science Now, 2005. 49 
Thailand 
In December 2004 Thai protesters released a statement to the national press accusing trial 
organizers of ignoring international ethical standards and exploiting injecting drug users. 50 On 
March 9, 2005, one day after a proposed trial of 1,600 IDUs in Bangkok received approval from 
Thailand's ethical review body, Thai AIDS advocacy organizations, lead by the Thai Drug 
Users' Network (TDN), held a press conference expressing their concerns regarding the planned 
trial. Patient's rights advocates criticized the failure of trial organizers to supply clean injecting 
equipment and expressed concern that different standards were being applied to the IDU 
participants than participants at high-risk because of sexual behavior. "In the African sites, 
condoms are offered as a matter of course to the trial participants, who are chose for their high 
risk sexual behavior," said Paisan Suwannawong, Director of the Thai AIDS Treatment Action 
Group (TTAG). The TDN also expressed concern over the planned management of new HIV 
infections diagnosed during screening for the trial and for persons who seroconvert during trial 
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participation. TDN and several other HIV advocacy organizations called on UNAIDS to 
intervene and postpone the start of the trial in order to allow better community involvement and 
resolution of perceived trial problems. Seree Jintakanon, chairman ofTDN, said, 
We 100 percent support research into new and better options for HIV prevention. But, 
tenofovir, which would have to be taken every day for the rest of one's life, costs nearly 
US$500/month. Trial participants would only get it free for one year. We are not hopeful 
that this method of prevention would be available for IDU or for ANY Thai person for 
that matter, ever. IfiDU and PLWHA were invited to be part of the process from the 
beginning, however, we might have negotiated better post-trial access. 51 
Community Involvement in Research Design and Implementation 
The interruption of the PrEP trials in Cambodia, Cameroon, and Thailand suggest a 
failure of trial sponsors to adequately assess, involve, and inform the target communities during 
critical stages of trial development. Over the past three decades, researchers have increasingly 
involved communities in the design of research. In addition, research participants, health 
advocates, and other members of the communities from which participants are recruited have 
requested, and in some cases demanded, involvement in the design of clinical trials. By 
consulting with the community, researchers often gain insight about whether the research 
question is relevant and responsive to health needs of the community involved. Further, 
community consultation can improve the informed consent process and resolve problems that 
arise due to the use of difficult or unfamiliar concepts. Such discussions can provide insight into 
whether the balance of benefits and harms in the study is considered acceptable and whether the 
interventions and follow-up procedures are satisfactory. Community consultation is particularly 
important when the researcher does not share the culture or customs of the population from 
which research participants will be recruited. For upcoming and future clinical trials of PrEP 
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and prior to the implementation of PrEP strategies in local communities, community assessment 
must be completed and community partnerships formed. 
MODELING THE IMP ACT OF PRE-EXPOSURE PROPHYLAXIS 
PrEP is unlikely to be completely effective in preventing the transmission ofHIV infection. 
Previously developed theoretical models for HIV preventive vaccines can be used to estimate the 
impact of PrEP efficacy, range of coverage, possible increases in risk behavior, and epidemic 
control. A model developed by Anderson and Garnett for low-efficacy HIV vaccines identifies 
several parameters that define the impact of the intervention, vaccine in this case, on the 
individual and the community. 52 Factors impacting at the individual level include: 
• Apparent efficacy of the intervention (vaccine or prophylaxis) 
• Duration of protection 
• Failure rate (fraction of individuals receiving the intervention who be come infected 
when exposed to the virus) 
• Relative infectiousness of individuals infected while receiving the intervention (vaccine 
or prophylaxis) compared with that of untreated individuals 
• Relative length of incubation period in individuals infected while receiving the 
intervention compared with that of untreated individuals 
Community factors to consider include the changes in sexual behavior after the introduction of 
the intervention, the partner exchange rate in the population and sex acts per partner. 
The authors conclude that for a vaccine with 80 percent efficacy in the setting of no 
significant behavior change and a life expectancy of 35 years of sexual activity, eradication of 
HIV infection would not be possible. Similar conclusions could be drawn about PrEP, which is 
likely to have an even lower efficacy than a vaccine offering partial protection. However, 
despite imperfect protection, communities can benefit from vaccines oflower efficacy. High 
population coverage with a vaccine of low efficacy could reduce the incidence and prevalence of 
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HIV infection. Additionally, with the use of behavioral and other prevention approaches, PrEP 
may act synergistically to further reduce the burden ofHN disease. 
PRE-EXPOSURE PROPHYLAXIS CHALLENGES 
Potential risks of antiretroviral PrEP include drug toxicity, reduced utilization of 
behavioral HN prevention measures and the acquisition of antiretroviral-resistant HN strains. 
Additional challenges exist with ensuring fair and equal access to prevention education and 
prevention strategies, including PrEP, and with assuring funding for PrEP medication and 
monitoring. 
Drug Toxicity 
As discussed above, tenofovir has been selected for the current trials of PrEP because of 
an excellent safety and tolerability profile. The most significant concerns regarding the safety of 
tenofovir relate to it's potential for kidney damage. Reports oftenofovir-associated renal 
toxicity in HN positive patients receiving combination antiretroviral therapy have increased in 
the medial literature. 53•54 Also, toxicities described for other nucleoside analogues, a class of HN 
medications that includes tenofovir, may apply to tenofovir as welL These toxicities include 
serious medical conditions such as lactic acidosis and lipodystrophy.55 The ongoing and planned 
clinical trials offer 1-2 years of monitoring following trial participation. It is possible that 
previously umecognized risks and adverse effects might develop in HIV negative recipients of 
PrEP. Given that with PrEP antiretroviral agents like tenofovir may be used either continuously 
or intermittently for prolonged periods of time, ongoing monitoring will be a critical part of 
clinical studies and of any broader implementation scheme. The frequency and duration of 
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safety monitoring for PrEP remains to be determined and future trials may be required to 
determine the optimal monitoring strategy. 
Behavior Change 
Current and future clinical trials will work to understand the impact of a daily drug 
regimen on HIV risk behaviors. Further study into the impact of PrEP on risk behaviors will be 
critical should tenofovir or another agent prove effective in reducing HIV transmission. One of 
the greatest risks is that persons at risk for HIV infection will reduce use of proven behavioral 
prevention strategies such as condom use. However, limited data on the use of PEP in high-risk 
persons suggests there is not an increase in risk -behavior in persons receiving PEP. 
Because it is likely that no single prevention strategy will be 100 percent effective against 
HIV transmission, reducing transmission will require determining how to integrate available 
prevention strategies, biomedical and behavioral, to optimize benefit. 44 Data collection on 
beliefs about PrEP and the development of educational strategies based on these findings must be 
completed prior to adoption of PrEP approaches. 
Adherence and Acceptability 
If clinical trials demonstrate that daily PrEP is effective and safe, implementation of PrEP 
strategies in a broader public health context will require that patients be willing to comply with 
daily dosing of medication. Future research must be aimed at assessing whether persons at risk 
are willing and able to maintain the daily regimen. Barriers to strict adherence will need to be 
identified and addressed as part of trial participation and for future use outside of clinical trials. 
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Drug Resistance 
As discussed above, clinical experience with the antiretroviral nevirapine has 
demonstrated the development of drug resistance in mothers and infants exposed to a single dose 
of nevirapine. Although resistance to tenofovir is uncommon among HN infected persons when 
used in combination with other antiretroviral medications, it is unclear how often resistance may 
develop if prophylaxis fails and PrEP recipients become infected with HN while taking 
tenofovir alone. For PrEP recipients who do develop HN infection during participation, concern 
exists that drug resistance may develop to the prophylactic agent, possibly limiting future HIV 
treatment options for the individual. 
Current clinical trials have adopted a strategy of frequent, regular HN testing to monitor 
for the development of new HN infection in trial participants: if study volunteers become 
infected, study medication will be immediately discontinued. Additionally, resistance testing 
will be provided to all persons infected during the trial and repeated 12 months after infection is 
detected. It is hoped that these data will provide important information on the frequency with 
which resistance occurs and will help guide treatment decisions as infected persons are referred 
to treatment and care. How to best monitor PrEP recipients outside of trial settings will need to 
be determined by additional studies. A balance will need to be met between safety, cost, and 
convenience in the monitoring strategy adopted for broad use. 
Access and Economics 
Should PrEP be effective in reducing the transmission ofHN infection, strategies for 
applying the research findings to at-risk populations will need to be developed. Challenges will 
exist in identifYing at-risk individuals, in the provision of medical evaluation, monitoring and 
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risk reduction counseling and in the provision of medication. Determining how best to cover the 
costs of PrEP will require collaboration between public health officials, community groups, 
representatives from the health industry, health insurers, and government officials 
RECOMMENDATIONS FOR POLICY ACTION AT THE STATE AND LOCAL PUBLIC 
HEALTH LEVELS 
Important findings on the effectiveness of PrEP strategies for the prevention ofHIV 
infection are likely to become available in the next three years. Safety information will be 
available as well, though the long-term effect of PrEP will only be determined by more extensive 
and prolonged follow up. If clinical trials suggest that PrEP is safe and effective, numerous 
clinical questions will need to be resolved prior to widespread implementation of PrEP strategies 
at the local public health levels. Since the systems developed within the context of a clinical 
trial are rarely reproducible in the community, a number of questions will need to be answered 
prior to implementing PrEP in local communities. 
In North Carolina, targeting PrEP interventions to the highest risk persons will require a 
complete analysis of populations at high risk for HN infection. The intervention would most 
likely target HN negative partners ofHN positive persons, men who have sex with men 
(MSM), female partners of MSM, and intravenous drug users and their partners. Other 
individuals who might be considered for PrEP could include commercial sex workers and 
persons in situations where HN risk is elevated, such as prisoners. A local assessment of 
community resources and factors impacting efficacy and safety will be important as well. 
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Prior to the availability of results from the ongoing and planned clinical trials of PrEP, 
the North Carolina public health system can begin to prepare for the possibility that the 
intervention will prove successful. The following recommendations outline important steps in 
preparation for the adoption of PrEP. 
• Convene a panel of key stakeholders to address if and how PrEP programs would be 
implemented and covered in the state ofNorth Carolina. The panel should include state 
government officials, representatives from state and local public health systems, HIV 
clinicians, health insurers, PrEP and prevention researchers, prevention counselors, 
community leaders and representatives from the conui:mnities most impacted by HIV. 
Issues to be address by the statewide stakeholder panel include: 
o Funding allocations for all aspects of PrEP: behavioral, social and biomedical 
• Convene an expert panel of researchers, prevention experts, clinicians and community 
representatives to develop recommendations for state-specific research that will need to 
be conducted prior to the implementation of PrEP programs. Specific questions to 
answer include: 
How to select candidates for PrEP 
o How to screen and counsel PrEP recipients for sexually transmitted diseases 
including HIV 
o How and by whom prophylactic medications will be provided (primary care 
physician, public health clinic) 
o How to best monitor patients receiving PrEP 
o How to manage persons that become HIV infected while on PrEP 
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• Conduct a community assessment in the communities most likely to be impacted by PrEP 
will need to be performed to answer a number of questions critical to the success of PrEP 
programs. Issues to address include: 
o Current use of safer sexual practices and other prevention methods 
o Impact of PrEP availability on risk behaviors and use of other prevention methods 
o Determining the extent of pre-existing PEP and PrEP use among at-risk 
individuals 
o The optimal approach to introducing and marketing PrEP to at-risk populations 
o Issues of access to healthcare services including role of race and gender in access 
CONCLUSIONS 
PrEP offers a novel approach to HIV prevention that may be a useful adjunct to current 
prevention approaches in the absence of an effective HN vaccine or microbicide. Current and 
planned clinical trials seek to answer critical questions about the safety and efficacy of PrEP in 
at-risk populations. While these clinical trials are likely to answer many questions about the role 
of PrEP in HN prevention, additional clinical, social and ethical questions will be raised. In 
anticipation of the results of these trials, the public health community should act proactively to 
answer many of the questions surrounding the use of PrEP in populations outside the context of 
clinical trials. By beginning to answer the myriad of questions likely to arise with this 
prevention strategy now, the public health system can better prepare themselves and the 
communities they serve for the implementation of PrEP or other HN prevention strategies in the 
future. 
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